

February 5, 2013

Astellas Pharma Inc.: Reorganization of Astellas' Global Management Structure

Astellas Pharma Inc. (Headquarters: Tokyo, President and CEO: Yoshihiko Hatanaka, "Astellas") announced that it will implement revisions to its global management structure including top management effective from April 1, 2013. The details of the revisions are provided below.

【Top Management Structure】

A new C-suite position of Chief Medical Officer (CMO) reporting directly to the President & CEO will be established in order to further integrate and enhance Astellas' delivery of global medical solutions. Additionally, Astellas will promote the global enhancement of the Medical and Pharmacovigilance functions in order to maintain the quality of Astellas' branded products based on medical need. Sef Kurstjens, M.D., Ph.D., currently President and CEO of Agensys, Inc., will take up the post of CMO.

(Implementations)

Title	Divisional Responsibilities
President and CEO (Chief Executive Officer)	Internal Auditing, Drug Discovery Research, <u>APGD</u> *1, QA&RA (GQA, GCRQA, GRA) *2, Technology, Sales & Marketing, Asia International, <u>APEL</u> *3, <u>AUS</u> *4, Agensys
Executive Vice President, CAO&CCO (Chief Administrative Officer & Chief Compliance Officer)	External Relations, General Affairs, Human Resources, Legal & Compliance, Executive Office
Senior Vice President and CFO (Chief Financial Officer)	Corporate Finance & Control, Accounting & Tax, Corporate Communications, Procurement, Information Systems
Senior Vice President and CSTO (Chief Strategy Officer)	Corporate Planning, Product and Portfolio Strategy, Licensing & Alliances, Intellectual Property, Global Vaccine Business Development
CMO (Chief Medical Officer)	<u>GPV</u> *2, <u>GMA</u> *5

* 1: Astellas Pharma Global Development, Inc.

* 2: Global Quality Assurance

Global Clinical and Research Quality Assurance

Global Regulatory Affairs

Global Pharmacovigilance

* 3: Astellas Pharma Europe Ltd. * 4: Astellas US LLC * 5: Global Medical Affairs

【Global Management Structure】

Further Enhancement of Global Pharmacovigilance and Product Compliance

(Objectives)

It is imperative to deliver to patients products which are fully compliant with local/regional regulations, including the most current safety information. In support of this, Astellas will pursue the further enhancement of global Quality Assurance (QA), Regulatory Affairs (RA) and Pharmacovigilance (PV) as well as increased operational excellence in these functions.

(Implementation)

All related functions in each region will be globally integrated under one global leader for the respective functions as follows:

Global Pharmacovigilance Overview

- A new position of “Global PV Head” which manages all regional PV organizations will be established. (The location of this position will be in Northbrook, Illinois, USA.)
- PV organization and function in each region as well as EU-QPPV (Qualified Person for PV) will continue to exist.

Global Product Compliance (Global QA, Global CRQA and Global RA) Overview

- New positions of global functional heads, which manages all regional organizations for QA, Clinical Research Quality Assurance (CRQA) and RA respectively, will be established. They will report to the QA & RA head in Astellas Pharma Inc. (The location of Global QA head will be in Tokyo, and the Global CRQA head and Global RA head will be in Northbrook, Illinois, USA.)
- QA, CRQA and RA functions in each region will continue to exist.

For inquiries or additional information
Astellas Pharma Inc. Corporate Communications TEL: +81-3-3244-3201, FAX:+81-3-5201-7473 http://www.astellas.com/en